Fomin V V, Тernovoy S K, Makhov V M, Isaykina M A, Dzhenzhera N А, Turko T V, Ugryumova L N, Babenko O V
I. M. Sechenov First Moscow state medical University, Ministry of Health of Russia (Sechenovskiy University), Moscow, Russia.
Ter Arkh. 2018 Feb 15;90(2):53-58. doi: 10.26442/terarkh201890253-58.
Assessment of diagnostic significance of informativeness and security of ultrasonography with contrast enhancement drug SonoVue in the diagnosis of Crohn's disease (CD) and ulcerative colitis (UC).
The pilot conducted a prospective study which involved 15 patients with inflammatory bowel disease (IBD). All patients gave written consent to participate in the study and processing of personal data. The study included adult patients with an established diagnosis of UC and CD, with proven clinical activity of the disease. Activity was evaluated based on clinical and laboratory data on the scale of best (CDAI >150) for patients with CD and on a scale of Trulove-Witts (2-3 stage) and the Mayo index (DAI) for patients with UC. All the patients underwent colonoscopy with biopsy, ultrasound examination of abdominal cavity organs with the study of the vascularization of the intestinal wall (color Doppler, power Doppler, contrast study).
The use of contrast showed additional features in the instrumental evaluation of activity of inflammatory process, identification of complications and assessment of prognosis.
The results of ultrasound of the bowel with contrast can be used to assess the activity and stage of disease in patients with UC or CD.
评估使用造影剂声诺维增强超声检查在克罗恩病（CD）和溃疡性结肠炎（UC）诊断中的信息性和安全性的诊断意义。
该试点进行了一项前瞻性研究，纳入15例炎症性肠病（IBD）患者。所有患者均书面同意参与研究及个人数据处理。研究纳入已确诊UC和CD且疾病临床活动得到证实的成年患者。对于CD患者，基于临床和实验室数据，按照最佳（CDAI>150）标准评估活动度；对于UC患者，按照特鲁洛夫-维茨标准（2 - 3期）和梅奥指数（DAI）评估活动度。所有患者均接受结肠镜检查及活检、腹腔器官超声检查并研究肠壁血管化情况（彩色多普勒、能量多普勒、造影研究）。
造影剂的使用在炎症过程活动度的仪器评估、并发症识别及预后评估方面显示出额外特征。
肠道超声造影结果可用于评估UC或CD患者的疾病活动度和分期。
